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Introduction 
Visceral pain is the most common form of pain that human beings suffer throughout a
lifetime. This kind of pain has important clinical characteristics:
• Is a pain originating in the internal organs but not evoked from all viscera.
• Diffuse and poorly localized.
• Not always linked to injury of the tissue.
• Referred to somatic structures.
• Intense motor and autonomic responses.
Irritable Bowel Disease (IBS) is mainly characterized by presence of visceral
hypersensitivity and affects 3-25%1 of the population. Among the wide variety of
treatment options of the visceral pain, probiotics appear to be one of the best options.
”Live microorganisms which when administered in adequate amounts confer a health benefit
on the host”. For being effective, they need the following conditions:
• Non pathogenic and non toxic.
• Able to maintain good viability.
• Able to survive the passage through the digestive system.
• Able to attach to the intestinal epithelia and colonize temporarily.
• Capable of exerting a proven beneficial effect on the host.
• Remain stable and viable during processing, storage and use.
The species most widely used Lactobacillus and Bifidobacterium.
Materials and methods 
This project has been made by the search and extended reading of recent papers obtained
from PubMed, Sciencedirect and Scopus databases, also consulting some doctoral thesis
and books. The information was selected according to their relevance and date. The main
key words used were: “visceral hypersensitivity”, “probiotic”, “probiotic AND visceral pain”,”
probiotic AND IBS”.
To evaluate whether the treatment with the probiotic species Lactobacillus and
Bifidobacterium is effective reducing the intestinal hyperalgesia in IBS patients.

Aims 
Results
PROBIOTICS 
IBS- related 
visceral pain 
• CB2 Receptor
• -opioid Receptor
Expression of: 
Enhancement of the 
barrier function 2
Release of Nitric oxide 
Expression of tight 
junction proteins :
• Occludin
• Zonula occludens – 1 (ZO1)
Apoptosis
Modify the cytokine profiles 
ratio IL-10/IL-12
Anti-inflammatory effect3
Modulation  of the microbiome- gut-
brain axis 
Changes in neurotransmitters 
levels in the SNC 4
Further studies needed… 
Immunomodulation 
Visceral pain Probiotics
0
10
20
30
40
50
60
70
62.5%
(20)
37.5%
(12)
0
10
20
30
40
50
60
Effective Non effective A single strain Multispecie
45%
(9)
55%
(11)
0
10
20
30
40
50
60
P
a
ti
e
n
ts
 s
h
o
w
in
g
 i
m
p
r
o
v
e
m
e
n
t 
in
 v
is
c
e
r
a
l 
p
a
in
(
%
)
 
Efficacy of probiotics reducing the intestinal hyperalgesia in IBS patients
Mechanism of  action of probiotics 
References
To elucidate the probiotics’ main mechanisms that promote the intestinal antinociception.
Compare the efficacy of using probiotics composed with a single strain or with multispecies. 
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Figure 1. Percentage of studies that showed
efficacy or non efficacy to the probiotical
treatment. There are more studies that showed good
response and a reduction of the visceral pain (62.5%)
than studies that didn’t show effectiveness (37,5%) to
the treatment with probiotics.
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Figure 2. Efficacy comparison between the use of
a single probiotic strain vs multispecies. From all
studies where patients showed an improvement in the
visceral pain, 45% used a single probiotic strain and
55% multispecies. There aren’t efficacy differences
between them.
Figure 3. Most effective probiotic strain
reducing the visceral pain.
Current evidence indicates that different probiotic strains mediate their effects by a
variety of different mechanisms that are dependent on the dosage employed , the
specific strain, as well as the frequency of delivery.
Although the exact mechanisms of action of probiotics
for the reduction of visceral pain are not known,
several have been proposed.
Figure 4. Lactobacillus acidophilus
NCFM induces the expression of MOR1
and CB2 in epithelial cells.
Rousseaux C et al. Nat. Med. 13, 35–7 (2007).
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Evidence suggests that probiotics offer a promise for the treatment of IBS patients. They
have shown efficacy reducing the visceral pain and there are several mechanisms
involved in this effect that are specie-specific.
Future studies are needed about best strains, use of single or mixtures probiotics, dosis
and to understand better the mechanisms involved in antinociception.


Conclusions
1. Cremoni F et al. Gastroenterol Clin North Am. 34, 189-204 (2005). 
2. Menningen R et al. Am J Physiol Gastrointest Liver Physiol.296, G1140-G1149(2009).
3. O’Mahony L et al. Gastroenterology.128, 541–51 (2005).  
4. Kannampalli P et al. Neurogastroenterol Motil. 26, 1694-704 (2014).
